Latest news with #MariamSunny
The Star
7 days ago
- Automotive
- The Star
STMicro to buy part of NXP Semiconductors' sensor business for up to $950 million
FILE PHOTO: The logo of electronics and semiconductors manufacturer STMIcroelectronics is seen outside a company building in Montrouge, near Paris, France, July 12, 2022. REUTERS/Sarah Meyssonnier/File Photo (Reuters) -French-Italian chipmaker STMicroelectronics said on Thursday it would acquire part of NXP Semiconductors' sensor unit for up to $950 million in cash. The deal would expand STMicro's portfolio of MEMS-based electromechanical sensors, which include safety and monitoring sensors for vehicles as well as pressure sensors for industrial applications. The unit generated revenue of about $300 million last year, STMicro said in a statement. As part of the agreement, STMicro would make an upfront payment of $900 million and $50 million on achieving certain technical milestones. The deal is expected to close in the first half of 2026. Chipmakers exposed to the struggling automotive, industrial, and consumer chip markets have faced a sales slump as they grapple with low demand and high inventories. Earlier in the day, STMicro, one of Europe's largest chipmakers, reported its first quarterly loss in over a decade as it took a $190 million hit from restructuring and impairment costs. (Reporting by Mariam Sunny in Bengaluru; Editing by Anil D'Silva)
USA Today
08-07-2025
- Health
- USA Today
CDC ends emergency response for bird flu as infections decline
The U.S. Centers for Disease Control and Prevention said on Monday it has ended its emergency response for H5N1 bird flu, owing to a decline in animal infections and no reports of human cases since February. The emergency response was deactivated on July 2, the agency told Reuters, adding that surveillance and response for bird flu cases will continue under the purview of its influenza division. The updates for bird flu was merged with routine updates for seasonal influenza, the agency's website showed on Monday. The number of people monitored and tested for bird flu will be reported on a monthly basis, the agency said, adding that it will no longer report infection rates in animals on its website. The virus has infected 70 people, mostly farm workers, and killed one person over the past year as it spread aggressively among cattle herds and poultry flocks. Experts have warned that further spread of bird flu raises the risk of it becoming more transmissible to humans. The current public health risk from H5N1 bird flu remains low, CDC said, adding that it will continue to monitor the situation and scale up activities as needed. The country's response to bird flu has faced several disruptions this year, including from staff exodus at the U.S. Department of Agriculture as part of the Trump administration's wider efforts to shrink the federal workforce and the government cancelling a more than $700 million contract awarded to Moderna MRNA.O for the late-stage development of its bird flu vaccine for humans. Bloomberg News first reported that CDC has ended its emergency response for bird flu. Emergency activation allows for additional support for a public health response, including staffing and other resources, to increase testing, surveillance and communications during an outbreak, according to CDC. The CDC H5N1 bird flu response was activated on April 4, 2024. (Reporting by Mariam Sunny in Bengaluru, additional reporting by Kamal Choudhury; Editing by Shilpi Majumdar and Shailesh Kuber)
Zawya
30-06-2025
- Business
- Zawya
Moderna's influenza vaccine superior to licensed shot in study
Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study. Shares of the company were up 2.3% in premarket trading following the results. Moderna said it plans to engage with regulators on filing submissions for the vaccine candidate, mRNA-1010. (Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo)
Yahoo
07-05-2025
- Health
- Yahoo
Europe reviews Valneva's chikungunya vaccine after reports of serious side effects
(Reuters) -The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after reports of serious side effects in older adults. The European Medicines Agency's (EMA) safety committee has temporarily suspended the use of the vaccine, branded as Ixchiq, in adults aged 65 years and older. The company said it will continue to monitor the reported events and cooperate with health authorities, while actively exploring a potential update to the vaccine's indication. Ixchiq -- the first preventive shot against chikungunya virus to be authorized in the Europe as well as the U.S. -- contains a weakened strain of the virus that triggers the immune system to make antibodies. The vaccine carries the risk of causing severe chikungunya-like adverse reactions, the EMA said in a statement. Chikungunya is a mosquito-borne disease caused by the chikungunya virus. The most common symptoms of the infection are fever and joint pain. About 17 serious adverse events, including two deaths, have been reported so far globally in people aged between 62 and 89 years who had received the vaccine, the agency said. Two men aged 84 years and 77 years who had received the vaccine died in the French overseas territory of La Reunion, where a recent chikungunya outbreak has been reported. The exact cause of the adverse events and their relationship with the vaccine have not yet been determined, the agency said, adding that the affected individuals also had other health conditions. The French government suspended the use of the vaccine in persons aged 65 years and older last month pending investigation. Advisers to the U.S. Centers for Disease Control and Prevention had recommended the vaccine last month for adults traveling to a country or territory where there is a chikungunya outbreak. The recommendation is yet to be signed off by the CDC. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Shinjini Ganguli)
Reuters
07-05-2025
- Health
- Reuters
Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people
Valneva logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights , opens new tab Companies Valneva SE Follow May 7 (Reuters) - The European Union's health regulator said on Wednesday it has begun a review of Valneva's ( , opens new tab chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid Our Standards: The Thomson Reuters Trust Principles. , opens new tab Share X Facebook Linkedin Email Link Purchase Licensing Rights
